Clinical Trial Update: PREclinical Mutation CARriers From Families With DIlated Cardiomyopathy and ACE Inhibitors [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating ACE inhibitors in preclinical mutation carriers from families with dilated cardiomyopathy was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dilated Cardiomyopathy

Drugs mentioned

• ACE inhibitors

Snippet

Sponsor: Institut National de la Santé Et de la Recherche Médicale, France | Conditions: Dilated Cardiomyopathy | Phase 3 | Status: TERMINATED